Patent ID: 8318431

Claim:
A method of evaluating a stage of ovarian cancer or a survival rate of an ovarian cancer patient, which comprises: (a) detecting a deletion or an expression of the CTGF gene in a tissue derived from an ovary, and (b) evaluating the stage of ovarian cancer or the survival rate of the ovarian cancer patient, wherein the stage of ovarian cancer is estimated as Stage I or II if the deletion of the CTGF gene, or the absence of the expression of the CTGF gene is detected in the tissue, or the stage of ovarian cancer is estimated as Stage III or IV if the presence of expression of the CTGF gene is detected in the tissue; and/or the survival rate is estimated as low if the expression of the CTGF gene is relatively low in a case of Stage I or II, or the survival rate is estimated as low if the expression of the CTGF gene is relatively high in a case of Stage III or IV.